RT Journal Article
SR Electronic
T1 Abnormal Upregulation of Cardiovascular Disease Biomarker PLA2G7 Induced by Proinflammatory Macrophages in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.16.20175505
DO 10.1101/2020.08.16.20175505
A1 Yang Li
A1 Yongzhong Jiang
A1 Yi Zhang
A1 Naizhe Li
A1 Qiangling Yin
A1 Linlin Liu
A1 Xin Lv
A1 Yan Liu
A1 Aqian Li
A1 Bin Fang
A1 Jiajia Li
A1 Hengping Ye
A1 Gang Yang
A1 Xiaoxian Cui
A1 Yang Liu
A1 Yuanyuan Qu
A1 Chuan Li
A1 Jiandong Li
A1 Dexin Li
A1 Shiwen Wang
A1 Zhongtao Gai
A1 Faxian Zhan
A1 Mifang Liang
YR 2020
UL http://medrxiv.org/content/early/2020/08/18/2020.08.16.20175505.abstract
AB BACKGROUND Coronavirus disease 2019 (COVID-19) triggers distinct patterns of pneumonia progression with multiorgan disease, calling for cell- and/or tissue-type specific host injury markers.METHODS An integrated hypothesis-free single biomarker analysis framework was performed on nasal swabs (n = 484) from patients with COVID-19 in GSE152075. The origin of candidate biomarker was assessed in single-cell RNA data (GSE145926). The candidate biomarker was validated in a cross-sectional cohort (n = 564) at both nucleotide and protein levels.RESULTS Phospholipase A2 group VII (PLA2G7) was identified as a candidate biomarker in COVID-19. PLA2G7 was predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, PLA2G7 was found in patients with COVID-19 and pneumonia, especially in severe pneumonia, rather than patients suffered mild H1N1 influenza infection. Up to 100% positive rates of PLA2G7 were positively correlated with not only viral loads in patients with COVID-19 but also severity of pneumonia in non-COVID-19 patients. Although Ct values of PLA2G7 in severe pneumonia was significantly lower than that in moderate pneumonia (P = 7.2e-11), no differences were observed in moderate pneumonia with COVID-19 between severe pneumonia without COVID-19 (P = 0.81). Serum protein levels of PLA2G7, also known as lipoprotein-associated phospholipase A2 (Lp-PLA2), were further found to be elevated and beyond the upper limit of normal in patients with COVID-19, especially among the re-positive patients.CONCLUSIONS We firstly identified and validated PLA2G7, a biomarker for cardiovascular diseases (CVDs), was abnormally enhanced in COVID-19 patients at both nucleotide and protein aspects. These findings provided indications into the prevalence of cardiovascular involvements seen in COVID-19 patients. PLA2G7 could be a hallmark of COVID-19 for monitoring disease progress and therapeutic response.FUNDING This study was supported by grants from China Mega-Projects for Infectious Disease (2018ZX10711001), National Natural Science Foundation of China (82041023).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from China Mega-Projects for Infectious Disease (2018ZX10711001), National Natural Science Foundation of China (82041023).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was approved by the human bioethics committee of the Chinese Center for Disease Control and Prevention, and all participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets GSE152075 and GSE145926 for this study can be found in the Gene Expression Omnibus (GEO) database hosted by the National Center for Biotechnology Information of the US National Institutes of Health (https://www.ncbi.nlm.nih.gov/geo/). All data are available in the main text or the supplementary materials.